DEBRA DAVIS: Open Payments
NPI 1417117953 · FOLEY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,005 in 102 payments from 17 companies in 2025. Trend: 2023 $20,086 · 2024 $2,551 · 2025 $2,005
Food & beverage: $2,005
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $571 |
| Lilly USA, LLC | 14 | $258 |
| AstraZeneca Pharmaceuticals LP | 10 | $256 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $190 |
| GlaxoSmithKline, LLC. | 3 | $152 |
| Novo Nordisk Inc | 13 | $148 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $79 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Exact Sciences Corporation | 3 | $52 |
| Amgen Inc. | 3 | $42 |
Products named: VRAYLAR, QULIPTA, MOUNJARO, CAPLYTA, FARXIGA, Ozempic, AREXVY, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
